US20190125648A1 - Composition for preventing, improving or treating hair loss comprising deoxycholic acid as active ingredient - Google Patents
Composition for preventing, improving or treating hair loss comprising deoxycholic acid as active ingredient Download PDFInfo
- Publication number
- US20190125648A1 US20190125648A1 US16/093,997 US201616093997A US2019125648A1 US 20190125648 A1 US20190125648 A1 US 20190125648A1 US 201616093997 A US201616093997 A US 201616093997A US 2019125648 A1 US2019125648 A1 US 2019125648A1
- Authority
- US
- United States
- Prior art keywords
- hair
- composition
- hair loss
- deoxycholic acid
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Definitions
- the present invention relates to a composition comprising deoxycholic acid as an effective ingredient for preventing, alleviating or treating hair loss.
- Hair loss has been one of the greatest worries for someone with the recent increase of interest in appearance. Hair loss has been a concern, for the most part, in men in their 40's to 50's. Recently, alopecia has spread to youth in their 20's and 30's. An increasing population of women is also reported to suffer from hair loss nowadays. A variety of environmental factors including diet imbalance, harmful air, polluted drinking water, acidic rain, and stress aggravate hair loss in people at the present day. Therefore, many studies are ongoing for prevention and treatment of hair loss.
- Each hair grows in cycles of various stages consisting of anagen in which hairs grow, catagen which signals the end of the active growth of a hair, with the regression of a hair bulb, Talogen in which the dermal papilla rests while a hair remains on the scalp, and exogen in which the dermal papilla starts to act or a new hair grows while an old hair is shed.
- Anagen stage (2-7 years) is an active growth period of a hair and is divided into two stages of producing hair which grows outwards from the bulb into hair follicles; and generating hard keratins in the hair follicles. The hair continues to grow itself until the catagen stage.
- Catagen stage (2-3 weeks) is a period during which hair growth ceases and the metabolism slow down while maintaining the shape of the hair. At this stage, keratin is not produced. The catagen stage accounts for 1% of total hair growth. At this stage, the hair bulb shrinks and is divided into dermal papilla, and is surrounded by hair follicles and travels upwards. The cell division is ceases.
- Talogen stage is a period during which the dermal papilla shrinks and the hair follicle gradually shrinks, and the hair root crawls upwards and falls out. It is the period of hair loss until the next stage of growth and lasts for 3 to 4 months.
- hairs in the anagen stages are predominant over those in the other stages whereas people with alopecia have hairs mostly in the Talogen stage, with a phenomenon of hair loss visible to a naked eye.
- the period of the anagen stage is shortened, resulting in the miniaturization of the hair. Accordingly, allowing the hair follicle in the Talogen stage to rapidly proceed to the anagen stage and prolonging the anagen stage are important for treatment of hair loss.
- Minoxidil transdermal agent
- finasteride oral agent
- Minoxidil was developed as an oral antihypertensive vasodilator medication and is now used as a topical agent for treatment of androgenic alopecia because hypertrichosis was observed in patients administered therewith.
- minoxidil which is a pyrimidine derivative, acts as a vasodilator to topically increase blood flow to activate keratinocytes whereby the progress of hair loss can be delayed and hairs in a new anagen stage appear. Thanks to this effect, minoxidil is widely used as a medication for hair loss treatment.
- finasteride is the first oral medication approved for treatment of androgenic alopecia by the FDA in 1997 and at present, is used worldwide by about 2.6 million persons.
- minoxidil has side effects including weight gain, edema, increased heart rates, angina pectoris, dermatitis, and itching.
- minoxidil has side effects including weight gain, edema, increased heart rates, angina pectoris, dermatitis, and itching.
- finasteride male sexual dysfunction was reported as a clinical case.
- These medications are thus limited in application or patients themselves are reluctant to use the medications.
- the interest of consumers in the prevention of hair loss and the promotion of hair regrowth has turned toward safe agents derived from natural materials and therefore, active studies therefor are ongoing.
- an object of the present invention is to provide a pharmaceutical composition for preventing, alleviating or treating hair loss.
- Another object of the present invention is to provide a quasi-drug composition for preventing or alleviating hair loss.
- a further object of the present invention is to provide a cosmetic composition for preventing or alleviating hair loss.
- the present invention provides a pharmaceutical composition comprising deoxycholic acid as an effective ingredient for preventing, alleviating or treating hair loss.
- the present invention provides a quasi-drug composition comprising deoxycholic acid as an effective ingredient for preventing or alleviating hair loss.
- the present invention provides a cosmetic composition comprising deoxycholic acid as an effective ingredient for preventing or alleviating hair loss.
- the present inventors have conducted research to develop an agent for treatment, alleviation, or treatment of hair loss.
- deoxycholic acid a bile acid
- a hair regrowth effect is found to promote the growth and proliferation of follicular cells, thus ultimately exerting a hair regrowth effect.
- Deoxycholic acid which is used as the effective ingredient of the present invention, is a representative secondary bile acid, represented by the empirical formula C24H40O4, which is derived from cholic acid.
- deoxycholic acid and its salts are construed to fall within the scope of deoxycholic acid.
- hair loss refers to a loss of hair from the scalp or to hair thinning and can be interchangeable with alopecia.
- hair loss include male-pattern hair loss (androgenic hair loss), alopecia areata, Talogen effluvium, drug-induced alopecia, mechanical alopecia, alopecia caused by a skin disorder, and cicatrical alopecia.
- hair loss should be understood to encompass all symptoms classified as hair loss in the art irrespective of whether the cause is direct or indirect.
- the composition of the present invention is used for preventing hair loss or promoting hair growth or regrowth.
- preventing hair loss means pertaining to preventing and suppressing alopecia as described above
- hair growth means pertaining to prolonging the life of hair in the anagen stage to allow hairs to appear thick and healthy
- hair regrowth means pertaining to inducing or promoting the generation of hair in a new anagen stage. Therefore, the composition of the present invention may be used as a hair loss preventing agent, a hair growth agent, and/or a hair restorer.
- composition of the present invention may be formulated into suitable forms according to product modalities (pharmaceutical composition, quasi-drug composition, or cosmetic composition).
- the composition of the present invention may be in a form selected from the group consisting of a tonic, a spray, a cream, a lotion, an aerosol, oil, a solution, a suspension, a gel, an ointment, a paste, an emulsion, a liniment, a tablet, a capsule, a powder and a granule.
- the composition of the present invention is an external skin preparation.
- composition of the present invention may comprise a different effective ingredient in addition to deoxycholic acid.
- the different effective ingredient contained in the composition of the present invention is polyphenol.
- the polyphenol available for the present invention may be exemplified by resveratrol, protocatechuic acid, gallic acid, p-hydroxybenzoic acid, caffeic acid, chlorogenic acid, cuomaric acid, ferulic acid, sinapic acid, pelargonidin, peonidin, delphinidin, malvidin, quercetin, myricetin, apigenin, luteolin, hesperetin, naringenin, eriodictyol, daidzein, genistein, glycitein, catechin and epicatechin.
- the polyphenol is resveratrol.
- the composition of the present invention comprises 0.1-10% by weight of deoxycholic acid.
- the pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier may be one typically utilized for formulation and examples thereof include, but are limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
- the pharmaceutical composition of the present invention may further comprise a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, etc.
- composition of the present invention may be administered orally or parenterally (e.g., transdermally).
- the suitable dose of the pharmaceutical composition of the present invention may vary depending on various factors including the formulation method, the patient's age, weight, sex, the period of hair loss, the state of hair loss, the time of administration, the route of administration, excretion rate, and response sensitivity and a skilled physician with a moderate level of experience can easily determine and prescribe an effective dose for the desired prevention or treatment.
- the pharmaceutical composition may be prepared in a unit dose form or prepared to be contained in a multi-dose container by formulating with a pharmaceutically acceptable carrier and/or excipient, according to a method that a person skilled in the art can easily perform.
- the formulation may be in the form of a solution in oil or aqueous medium, a suspension, or an emulsion, or an extract, powders, granules, tablets, or capsules and may further include a dispersing agent or stabilizer.
- a quasi-drug refers to a product that has a weak action on the human body or does not directly act on the human body and which is not a tool or a machine, but an analogue thereof.
- a notice from the ministry of health and welfare in Korea classifies an external use agent for prevention of hair loss or promotion of hair regrowth as a quasi-drug.
- a cosmetic refers is defined as a product that cleans or beautifies the human body to enhance the charm or appearance of a person or is applied to the human body to maintain or enhance the health of the skin or hair and which has a slight effect on the human body.
- the quasi-drug or cosmetic composition of the present invention may be prepared into any formulation form typically used in the art, for example, various external use agents such as paste, mousse, gel, liquid, emulsion, suspension, cream, ointment, sheet, aerosol, spray and liniment.
- various external use agents such as paste, mousse, gel, liquid, emulsion, suspension, cream, ointment, sheet, aerosol, spray and liniment.
- the quasi-drug or cosmetic composition of the present invention may be in the form of a hair shampoo, a hair rinse, a hair tonic, a hair conditioner, a hair essence, a hair lotion, a hair nutrient lotion, a hair cream, a hair nutrient cream, a hair moisturizing cream, a hair massage cream, a hair wax, a hair aerosol, a hair pack, a hair soap, a hair gel, a hair glaze, a hair mousse or a hair spray.
- composition comprising deoxycholic acid as an effective ingredient for preventing, alleviation, or treating hair loss.
- composition of the present invention can be used as a hair loss preventer, hair growth agent or hair restorer.
- FIG. 1 shows changes in the area of hair loss of group T (testosterone 10 mg/ml), group TD (testosterone 10 mg/ml+deoxycholic acid 1 mg/ml), and group TF (testosterone 10 mg/ml+finasteride 1 mg/ml).
- FIG. 2 shows counts of follicular cells in group T (testosterone 10 mg/ml), group TD (testosterone 10 mg/ml+deoxycholic acid 1 mg/ml), and group TF (testosterone 10 mg/ml+finasteride 1 mg/ml).
- FIG. 3 shows changes in the area of hair loss of group T (testosterone 10 mg/ml), group TR (testosterone 10 mg/ml+resveratrol 1 mg/ml), group TF (testosterone 10 mg/ml+finasteride 1 mg/ml), and group TRF (testosterone 10 mg/ml+resveratrol 1 mg/ml+finasteride 1 mg/ml).
- Testosterone was purchased from Wako Pure Chemical Industry, and deoxycholic acid, finasteride, resveratrol, and N-Methyl-2-pyrrolidone (NMP) were Sigma Aldrich. Ethanol and glycerol was purchased from OCI Company Ltd. and Biosesang Company Ltd., respectively.
- B6CBAF1/j hybrid mice (5 weeks old, male, Charles River Japan) were acclimated for one week in a breeding room and then used from the time of 6 weeks after birth.
- a solvent was prepared to contain 15% of ethanol, 5% of NMP, and 80% of PBS. Solutions were prepared by mixing the solvent with the following solutes: group T (testosterone 10 mg/ml), group TD (testosterone 10 mg/ml+deoxycholic acid 1 mg/ml), group TR (testosterone 10 mg/ml+resveratrol 1 mg/ml), group TF (testosterone 10 mg/ml+finasteride 1 mg/ml), and group TRF (testosterone 10 mg/ml+resveratrol 1 mg/ml+finasteride 1 mg/ml).
- mice were anesthetized with isoflurane through inhalation and injected subcutaneously at the neck with 100 ⁇ l of a testosterone solution (10 mg/ml) every day. From a couple of weeks, they were photographed along with a scale bar to quantify a hair loss area. After six weeks of testing, the mice were sacrificed by means of a CO 2 incubator. Test areas of the skin were taken, fixed with formalin, and prepared into paraffin blocks. The blocks were horizontally sectioned and dyed with H&E (Hematoxylin & Eosin) to count follicles per mm 2 .
- H&E Hematoxylin & Eosin
- the deoxycholic acid-treated group (group TD) was observed to remarkably reduce in hair loss area from week 3 after drug treatment, compared to the group treated with testosterone alone (group T).
- group T the group treated with testosterone alone
- group T the group treated with testosterone alone
Abstract
Description
- The present invention relates to a composition comprising deoxycholic acid as an effective ingredient for preventing, alleviating or treating hair loss.
- Hair loss has been one of the greatest worries for someone with the recent increase of interest in appearance. Hair loss has been a concern, for the most part, in men in their 40's to 50's. Recently, alopecia has spread to youth in their 20's and 30's. An increasing population of women is also reported to suffer from hair loss nowadays. A variety of environmental factors including diet imbalance, harmful air, polluted drinking water, acidic rain, and stress aggravate hair loss in people at the present day. Therefore, many studies are ongoing for prevention and treatment of hair loss.
- Each hair grows in cycles of various stages consisting of anagen in which hairs grow, catagen which signals the end of the active growth of a hair, with the regression of a hair bulb, Talogen in which the dermal papilla rests while a hair remains on the scalp, and exogen in which the dermal papilla starts to act or a new hair grows while an old hair is shed.
- Anagen stage (2-7 years) is an active growth period of a hair and is divided into two stages of producing hair which grows outwards from the bulb into hair follicles; and generating hard keratins in the hair follicles. The hair continues to grow itself until the catagen stage.
- Catagen stage (2-3 weeks) is a period during which hair growth ceases and the metabolism slow down while maintaining the shape of the hair. At this stage, keratin is not produced. The catagen stage accounts for 1% of total hair growth. At this stage, the hair bulb shrinks and is divided into dermal papilla, and is surrounded by hair follicles and travels upwards. The cell division is ceases.
- Talogen stage (3 months) is a period during which the dermal papilla shrinks and the hair follicle gradually shrinks, and the hair root crawls upwards and falls out. It is the period of hair loss until the next stage of growth and lasts for 3 to 4 months.
- For a normal person, hairs in the anagen stages are predominant over those in the other stages whereas people with alopecia have hairs mostly in the Talogen stage, with a phenomenon of hair loss visible to a naked eye. As the hair loss progresses, the period of the anagen stage is shortened, resulting in the miniaturization of the hair. Accordingly, allowing the hair follicle in the Talogen stage to rapidly proceed to the anagen stage and prolonging the anagen stage are important for treatment of hair loss.
- There are two kinds of medications approved for hair growth promotion by the FDA: minoxidil (transdermal agent) and finasteride (oral agent). Minoxidil was developed as an oral antihypertensive vasodilator medication and is now used as a topical agent for treatment of androgenic alopecia because hypertrichosis was observed in patients administered therewith. When applied to the scalp, minoxidil, which is a pyrimidine derivative, acts as a vasodilator to topically increase blood flow to activate keratinocytes whereby the progress of hair loss can be delayed and hairs in a new anagen stage appear. Thanks to this effect, minoxidil is widely used as a medication for hair loss treatment. Acting to inhibit type II 5α-reductase with the resultant effect of preventing hair loss and promoting hair regrowth, finasteride is the first oral medication approved for treatment of androgenic alopecia by the FDA in 1997 and at present, is used worldwide by about 2.6 million persons.
- However, minoxidil has side effects including weight gain, edema, increased heart rates, angina pectoris, dermatitis, and itching. For finasteride, male sexual dysfunction was reported as a clinical case. These medications are thus limited in application or patients themselves are reluctant to use the medications. For the reason, the interest of consumers in the prevention of hair loss and the promotion of hair regrowth has turned toward safe agents derived from natural materials and therefore, active studies therefor are ongoing.
- Throughout the entire specification, many papers and patent documents are referenced and their citations are represented. The disclosures of cited papers and patent documents are entirely incorporated by reference into the present specification, and the level of the technical field within which the present invention falls and details of the present invention are explained more clearly.
- Leading to the present invention, intensive and thorough research into the development of an agent for prevention, alleviation or treatment of hair loss, conducted by the present inventors, resulted in the finding that deoxycholic acid, which is a bile acid, promotes the growth and proliferation of follicular cells to ultimately exhibit a hair regrowth effect.
- Accordingly, an object of the present invention is to provide a pharmaceutical composition for preventing, alleviating or treating hair loss.
- Another object of the present invention is to provide a quasi-drug composition for preventing or alleviating hair loss.
- A further object of the present invention is to provide a cosmetic composition for preventing or alleviating hair loss.
- Other purposes and advantages of the present invention will become clarified by the following detailed description of the invention, claims, and drawings.
- According to one aspect thereof, the present invention provides a pharmaceutical composition comprising deoxycholic acid as an effective ingredient for preventing, alleviating or treating hair loss.
- According to another aspect thereof, the present invention provides a quasi-drug composition comprising deoxycholic acid as an effective ingredient for preventing or alleviating hair loss.
- According to a further aspect thereof, the present invention provides a cosmetic composition comprising deoxycholic acid as an effective ingredient for preventing or alleviating hair loss.
- The present inventors have conducted research to develop an agent for treatment, alleviation, or treatment of hair loss. As a result, deoxycholic acid, a bile acid, is found to promote the growth and proliferation of follicular cells, thus ultimately exerting a hair regrowth effect.
- Deoxycholic acid, which is used as the effective ingredient of the present invention, is a representative secondary bile acid, represented by the empirical formula C24H40O4, which is derived from cholic acid. Herein, deoxycholic acid and its salts are construed to fall within the scope of deoxycholic acid.
- As used herein, the term “hair loss” refers to a loss of hair from the scalp or to hair thinning and can be interchangeable with alopecia. Examples of the hair loss include male-pattern hair loss (androgenic hair loss), alopecia areata, Talogen effluvium, drug-induced alopecia, mechanical alopecia, alopecia caused by a skin disorder, and cicatrical alopecia.
- Therefore, the term “hair loss” should be understood to encompass all symptoms classified as hair loss in the art irrespective of whether the cause is direct or indirect.
- According to an embodiment, the composition of the present invention is used for preventing hair loss or promoting hair growth or regrowth.
- The term “preventing hair loss” means pertaining to preventing and suppressing alopecia as described above, the term “hair growth” means pertaining to prolonging the life of hair in the anagen stage to allow hairs to appear thick and healthy, and the term “hair regrowth” means pertaining to inducing or promoting the generation of hair in a new anagen stage. Therefore, the composition of the present invention may be used as a hair loss preventing agent, a hair growth agent, and/or a hair restorer.
- The composition of the present invention may be formulated into suitable forms according to product modalities (pharmaceutical composition, quasi-drug composition, or cosmetic composition).
- For example, the composition of the present invention may be in a form selected from the group consisting of a tonic, a spray, a cream, a lotion, an aerosol, oil, a solution, a suspension, a gel, an ointment, a paste, an emulsion, a liniment, a tablet, a capsule, a powder and a granule.
- According to an embodiment, the composition of the present invention is an external skin preparation.
- The composition of the present invention may comprise a different effective ingredient in addition to deoxycholic acid.
- According to an embodiment, the different effective ingredient contained in the composition of the present invention is polyphenol.
- The polyphenol available for the present invention may be exemplified by resveratrol, protocatechuic acid, gallic acid, p-hydroxybenzoic acid, caffeic acid, chlorogenic acid, cuomaric acid, ferulic acid, sinapic acid, pelargonidin, peonidin, delphinidin, malvidin, quercetin, myricetin, apigenin, luteolin, hesperetin, naringenin, eriodictyol, daidzein, genistein, glycitein, catechin and epicatechin.
- According to a more particular embodiment, the polyphenol is resveratrol.
- According to some embodiments, the composition of the present invention comprises 0.1-10% by weight of deoxycholic acid.
- The pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier.
- The pharmaceutically acceptable carrier may be one typically utilized for formulation and examples thereof include, but are limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
- In addition to the above-mentioned ingredient, the pharmaceutical composition of the present invention may further comprise a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, etc.
- For concrete suitable pharmaceutically acceptable carriers and agents, reference may be made to Remington's Pharmaceutical Sciences (19th ed., 1995).
- The pharmaceutical composition of the present invention may be administered orally or parenterally (e.g., transdermally).
- The suitable dose of the pharmaceutical composition of the present invention may vary depending on various factors including the formulation method, the patient's age, weight, sex, the period of hair loss, the state of hair loss, the time of administration, the route of administration, excretion rate, and response sensitivity and a skilled physician with a moderate level of experience can easily determine and prescribe an effective dose for the desired prevention or treatment.
- Additionally, the pharmaceutical composition may be prepared in a unit dose form or prepared to be contained in a multi-dose container by formulating with a pharmaceutically acceptable carrier and/or excipient, according to a method that a person skilled in the art can easily perform. In particular, the formulation may be in the form of a solution in oil or aqueous medium, a suspension, or an emulsion, or an extract, powders, granules, tablets, or capsules and may further include a dispersing agent or stabilizer.
- According to the Korean Pharmaceutical Affairs Act, a quasi-drug refers to a product that has a weak action on the human body or does not directly act on the human body and which is not a tool or a machine, but an analogue thereof. A notice from the ministry of health and welfare in Korea classifies an external use agent for prevention of hair loss or promotion of hair regrowth as a quasi-drug.
- In addition, according to the Korean cosmetics act, a cosmetic refers is defined as a product that cleans or beautifies the human body to enhance the charm or appearance of a person or is applied to the human body to maintain or enhance the health of the skin or hair and which has a slight effect on the human body.
- The quasi-drug or cosmetic composition of the present invention may be prepared into any formulation form typically used in the art, for example, various external use agents such as paste, mousse, gel, liquid, emulsion, suspension, cream, ointment, sheet, aerosol, spray and liniment.
- According to an embodiment, the quasi-drug or cosmetic composition of the present invention may be in the form of a hair shampoo, a hair rinse, a hair tonic, a hair conditioner, a hair essence, a hair lotion, a hair nutrient lotion, a hair cream, a hair nutrient cream, a hair moisturizing cream, a hair massage cream, a hair wax, a hair aerosol, a hair pack, a hair soap, a hair gel, a hair glaze, a hair mousse or a hair spray.
- Features and advantages of the present invention are summarized as follows:
- (a) The present invention provides composition comprising deoxycholic acid as an effective ingredient for preventing, alleviation, or treating hair loss.
- (b) Because deoxychloic acid promotes the proliferation and growth of follicular cells to ultimately exhibit the effect of hair regrowth, the composition of the present invention can be used as a hair loss preventer, hair growth agent or hair restorer.
-
FIG. 1 shows changes in the area of hair loss of group T (testosterone 10 mg/ml), group TD (testosterone 10 mg/ml+deoxycholic acid 1 mg/ml), and group TF (testosterone 10 mg/ml+finasteride 1 mg/ml). -
FIG. 2 shows counts of follicular cells in group T (testosterone 10 mg/ml), group TD (testosterone 10 mg/ml+deoxycholic acid 1 mg/ml), and group TF (testosterone 10 mg/ml+finasteride 1 mg/ml). -
FIG. 3 shows changes in the area of hair loss of group T (testosterone 10 mg/ml), group TR (testosterone 10 mg/ml+resveratrol 1 mg/ml), group TF (testosterone 10 mg/ml+finasteride 1 mg/ml), and group TRF (testosterone 10 mg/ml+resveratrol 1 mg/ml+finasteride 1 mg/ml). - Hereinafter, the present invention will be described in detail with reference to examples. These examples are only for illustrating the present invention more specifically, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples.
- Testosterone was purchased from Wako Pure Chemical Industry, and deoxycholic acid, finasteride, resveratrol, and N-Methyl-2-pyrrolidone (NMP) were Sigma Aldrich. Ethanol and glycerol was purchased from OCI Company Ltd. and Biosesang Company Ltd., respectively.
- Animal Preparation
- B6CBAF1/j hybrid mice (5 weeks old, male, Charles River Japan) were acclimated for one week in a breeding room and then used from the time of 6 weeks after birth.
- For use in an injection agent, a solvent was prepared to contain 15% of ethanol, 5% of NMP, and 80% of PBS. Solutions were prepared by mixing the solvent with the following solutes: group T (
testosterone 10 mg/ml), group TD (testosterone 10 mg/ml+deoxycholic acid 1 mg/ml), group TR (testosterone 10 mg/ml+resveratrol 1 mg/ml), group TF (testosterone 10 mg/ml+finasteride 1 mg/ml), and group TRF (testosterone 10 mg/ml+resveratrol 1 mg/ml+finasteride 1 mg/ml). - The animals were anesthetized with isoflurane through inhalation and injected subcutaneously at the neck with 100 μl of a testosterone solution (10 mg/ml) every day. From a couple of weeks, they were photographed along with a scale bar to quantify a hair loss area. After six weeks of testing, the mice were sacrificed by means of a CO2 incubator. Test areas of the skin were taken, fixed with formalin, and prepared into paraffin blocks. The blocks were horizontally sectioned and dyed with H&E (Hematoxylin & Eosin) to count follicles per mm2.
- As shown in
FIG. 1 , the deoxycholic acid-treated group (group TD) was observed to remarkably reduce in hair loss area fromweek 3 after drug treatment, compared to the group treated with testosterone alone (group T). Onweek 4, a similar effect was found between the deoxycholic acid-treated group (group TD) and the finasteride-treated group (group TF) (FIG. 1 ). In addition, it can be seen inFIG. 2 that remarkable proliferation and growth of follicular cells were detected in the deoxycholic acid-treated group (group TD), compared to the group treated with testosterone alone (group T). - Even after two weeks, as shown in
FIG. 3 , the hair loss continued to increase in the group treated with testosterone alone (group T) while an increment in hair loss area was greatly reduced in the group treated with resveratrol (group TR) and with resveratrol and finasteride in combination (group TRF) (FIG. 3 ). - Those skilled in the art will appreciate that the conceptions and specific embodiments disclosed in the foregoing description may be readily utilized as a basis for modifying or designing other embodiments for carrying out the same purposes of the present invention. Those skilled in the art will also appreciate that such equivalent embodiments do not depart from the spirit and scope of the invention as set forth in the appended claims.
Claims (9)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2016/008859 WO2018030560A1 (en) | 2016-08-11 | 2016-08-11 | Composition for preventing, improving or treating hair loss comprising deoxycholic acid as active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190125648A1 true US20190125648A1 (en) | 2019-05-02 |
Family
ID=61163017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/093,997 Abandoned US20190125648A1 (en) | 2016-08-11 | 2016-08-11 | Composition for preventing, improving or treating hair loss comprising deoxycholic acid as active ingredient |
Country Status (5)
Country | Link |
---|---|
US (1) | US20190125648A1 (en) |
EP (1) | EP3511006B1 (en) |
JP (1) | JP2019509333A (en) |
CN (1) | CN109195605A (en) |
WO (1) | WO2018030560A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102020006049A1 (en) | 2020-10-02 | 2022-04-07 | Radim Vlcek | deoxycholic acid and its compounds for use in the treatment of diseases |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4185099A (en) * | 1977-01-04 | 1980-01-22 | Also Laboratori S.a.S. di Dr.P. Sorbini & C | Hair and scalp treatment with compositions containing chenodeoxycholic or ursodeoxycholic acid |
FR2816843A1 (en) * | 2000-11-23 | 2002-05-24 | Actichem | 5-Alpha reductase inhibitor used for treating disorders due to excess dihydrotestosterone e.g. acne and alopecia comprise cis or trans resveratrol and its derivatives |
US20100160276A1 (en) * | 2007-06-19 | 2010-06-24 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid compositions and methods |
US8258146B2 (en) * | 2009-03-23 | 2012-09-04 | Fujifilm Corporation | Minoxidil aqueous composition containing bile acid |
KR20150019566A (en) * | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
US20190247406A1 (en) * | 2016-10-31 | 2019-08-15 | Samsung Life Public Welfare Foundation | Pharmaceutical composition for preventing or treating ischemia-reperfusion injury, containing bile acid |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1106287A (en) * | 1978-06-30 | 1981-08-04 | Paolo Sorbini | Chenodeoxycholic or ursodeoxycholic acids for hair and scalp treatment |
IT1258069B (en) * | 1992-04-10 | 1996-02-20 | COMPOSITION FOR TOPICAL USE WITH STIMULUS ACTIVITY FOR GROWTH, REGENERATION, PREVENTION OF ENRIGEMENT AND NATURAL REPIGMENTATION OF HAIR | |
ITFI20050031A1 (en) * | 2005-02-21 | 2006-08-22 | Stefan Coccoloni | A PHARMACEUTICAL COMPOSITION TO PREVENT THE AGING AND THE RISING OF VASCULAR, NEOPLASTIC, CUTANEOUS AND PILIFEROUS DISEASES |
US7618956B2 (en) * | 2005-05-31 | 2009-11-17 | The Gillette Company | Reduction of hair growth |
GB2480632A (en) * | 2010-05-25 | 2011-11-30 | Kythera Biopharmaceuticals Inc | Preparation of 12-keto and 12-alpha-hydroxy steroids |
US20140079686A1 (en) * | 2010-12-06 | 2014-03-20 | Shikha P. Barman | Methods For Treating Baldness And Promoting Hair Growth |
CN103120693A (en) * | 2011-11-17 | 2013-05-29 | 王诚 | Composition of anti-hair-loss agent |
KR101868208B1 (en) * | 2015-08-03 | 2018-06-18 | ㈜솔시온바이오메디칼 | Compositions for preventing, improving or treating hair loss comprising deoxycholic acid as an active component |
KR101620088B1 (en) * | 2015-11-24 | 2016-05-12 | 연세대학교 산학협력단 | Composition for Preventing or Treating Hair Loss or Stimulating Hair Sprouting or Hair Growth Comprising Geranic Acid as Active Ingredients |
-
2016
- 2016-08-11 US US16/093,997 patent/US20190125648A1/en not_active Abandoned
- 2016-08-11 JP JP2018560414A patent/JP2019509333A/en active Pending
- 2016-08-11 CN CN201680086223.1A patent/CN109195605A/en active Pending
- 2016-08-11 EP EP16912759.4A patent/EP3511006B1/en active Active
- 2016-08-11 WO PCT/KR2016/008859 patent/WO2018030560A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4185099A (en) * | 1977-01-04 | 1980-01-22 | Also Laboratori S.a.S. di Dr.P. Sorbini & C | Hair and scalp treatment with compositions containing chenodeoxycholic or ursodeoxycholic acid |
FR2816843A1 (en) * | 2000-11-23 | 2002-05-24 | Actichem | 5-Alpha reductase inhibitor used for treating disorders due to excess dihydrotestosterone e.g. acne and alopecia comprise cis or trans resveratrol and its derivatives |
US20100160276A1 (en) * | 2007-06-19 | 2010-06-24 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid compositions and methods |
US8258146B2 (en) * | 2009-03-23 | 2012-09-04 | Fujifilm Corporation | Minoxidil aqueous composition containing bile acid |
KR20150019566A (en) * | 2013-08-14 | 2015-02-25 | 주식회사 엘지생활건강 | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening |
US20190247406A1 (en) * | 2016-10-31 | 2019-08-15 | Samsung Life Public Welfare Foundation | Pharmaceutical composition for preventing or treating ischemia-reperfusion injury, containing bile acid |
Also Published As
Publication number | Publication date |
---|---|
JP2019509333A (en) | 2019-04-04 |
EP3511006A1 (en) | 2019-07-17 |
CN109195605A (en) | 2019-01-11 |
WO2018030560A1 (en) | 2018-02-15 |
EP3511006A4 (en) | 2019-11-20 |
EP3511006B1 (en) | 2021-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100992565B1 (en) | Topical preparations for hair growth | |
KR100769260B1 (en) | Compositions for hair improvement containing rare earth elements | |
US20180250213A1 (en) | Hair restoration/growth stimulating agent | |
CN109846773A (en) | A kind of scalp composition and its preparation method and application can inhibit alopecia seborrheica | |
US9408795B2 (en) | Method for enhancing the growth and fullness of hair | |
EP2066289A1 (en) | Uses of rare earth elements for hair improvement | |
KR101141779B1 (en) | Composition for promoting hair growth comprising extract or a saponin fraction of Codonopis lanceolata | |
JP2016523957A (en) | Composition for promoting hair growth and hair growth | |
KR101654308B1 (en) | Composition for improving hair having effect of depilation prevention and good hair | |
EP3511006B1 (en) | Composition for preventing, improving or treating hair loss comprising deoxycholic acid as active ingredient | |
KR19990018331A (en) | Hair growth promoting composition | |
KR101792402B1 (en) | Hair growth stimulants comprising nicotinic acid adenine dinucleotide phosphate and its derivatives | |
KR20030062605A (en) | Hair growth compositions using natural fermentation extract of herbs | |
KR101307304B1 (en) | Composition for treating hair or scalp to prevent hair loss and promote growing hair | |
US11045510B2 (en) | Combination of aqueous extracts of watercress and nasturtium and ATP for use in the treatment of alopecia | |
KR101868208B1 (en) | Compositions for preventing, improving or treating hair loss comprising deoxycholic acid as an active component | |
JP2001278750A (en) | New hair-growing agent | |
JP2001139436A (en) | Hair tonic and grower | |
JP3142309B2 (en) | Hair restorer | |
KR20090052652A (en) | Composition for preventing gray hair and for treatment of leukoplakia containing arrowroot | |
US10265299B2 (en) | Composition for promoting hair growth and/or hair restoration containing psoralidin | |
KR20020008268A (en) | Testosterone 5 alpha-reductase inhibitors containing extracts of galla rhois | |
KR100308491B1 (en) | Composition for growthing hair | |
KR20120046564A (en) | Compositions for scalp-care and hair restoration containing extracts of melia azedarach fruits as an effective ingredient | |
KR20100007003A (en) | Composition for preventing hair loss or promoting hair growth comprising an extract of crataegis fructus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, KOREA, REP Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GWON, HYEON-CHEOL;LEE, DONG YOUN;JANG, HYUNG-SUK;AND OTHERS;REEL/FRAME:047178/0357 Effective date: 20180810 Owner name: SOLSION BIOMEDICAL INC., KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GWON, HYEON-CHEOL;LEE, DONG YOUN;JANG, HYUNG-SUK;AND OTHERS;REEL/FRAME:047178/0357 Effective date: 20180810 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: AWAITING RESPONSE FOR INFORMALITY, FEE DEFICIENCY OR CRF ACTION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |